Covid Vaccines: different types, risks/benefits, and the body as a factory.
December 9 @ 5:00 pm - 6:30 pm
Join us for an in-depth discussion on the types of vaccines being developed for COVID with special attention on mRNA vaccines from Moderna and Pfizer with Marco Lobba, UC Berkeley PhD candidate and CEO of startup Catena Biosciences.
Marco J. Lobba is Co-Founder and CEO of Catena Biosciences. As a PhD candidate at UC Berkeley in the labs of Matt Francis and Jennifer Doudna, Marco developed the technology behind Catena Biosciences that enables the creation of novel therapeutics and vaccine candidates. Marco has worked extensively in the Doudna lab on delivery of CRISPR proteins and the discovery of novel anti-CRISPRs for use in modulating CRISPR activity. In the Francis lab he has contributed to the study of viral capsid assembly and modification. Marco has a BA in Chemistry from Pomona College and previously worked as the Quality Control Manager at Anresco Laboratories.
Catena Biosciences- Founded in Fall 2020 amidst the COVID-19 pandemic, Catena is based on technology developed at UC Berkeley between the labs of Matt Francis and Jennifer Doudna. Our novel platform allows for the rapid creation of protein fusion therapeutics for vaccines and cancer immunotherapy. Catena’s mission is to create cures for diseases previously thought incurable and to increase accessibility to treatment by lowering costs on production and screening.